Title: Efficacy and safety of the combination of camrelizumab and apatinib in the treatment of
liver cancer: a systematic review and single-arm meta-analysis
Version: 1 Date: 09 Jan 2024
Reviewer's report:
The manuscript has been quite improved.
As minor comment, I only suggest to expand the discussion about the strength and the limitations
of CARES trial in light of the considerations reported in the accompanying editorial (PMID:
36174622 )
Title: Efficacy and safety of the combination of camrelizumab and apatinib in the treatment of
liver cancer: a systematic review and single-arm meta-analysis
Version: 1 Date: 09 Jan 2024
Reviewer's report:
The manuscript has been quite improved.
As minor comment, I only suggest to expand the discussion about the strength and the limitations
of CARES trial in light of the considerations reported in the accompanying editorial (PMID:
36174622 )
Please review this paper.
user
Title: Efficacy and safety of the combination of camrelizumab and apatinib in the treatment of
liver cancer: a systematic review and single-arm meta-analysis
Version: 1 Date: 09 Jan 2024
Reviewer's report:
The manuscript has been quite improved.
As minor comment, I only suggest to expand the discussion about the strength and the limitations
of CARES trial in light of the considerations reported in the accompanying editorial (PMID:
36174622 )
assistant